Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report

  • Shahla Abu Naib1
  • Marco Gerlinger1,2
  1. 1Leaders in Oncology Care, HCA Healthcare UK
  2. 2Barts Cancer Institute, Queen Mary University of London
Open at sourceDOICite

Abstract

Urachal adenocarcinoma is a rare malignancy without prospective treatment trials. Management of metastatic disease is typically extrapolated from colorectal cancer (CRC) due to histologic and molecular similarities. An 80-year-old woman with metastatic urachal adenocarcinoma received sequential CRC-based therapy including first-line CAPOX plus bevacizumab, second-line FOLFIRI plus bevacizumab, third-line trifluridine/tipiracil plus bevacizumab, in addition to brief administration of regorafenib and fruquintinib in the fourth- and fifth-line setting. Oxaliplatin was discontinued after one cycle due to worsening of vision on a background of pre-existing retinopathy. The longest disease control (time to progression ~11 months) occurred with trifluridine/tipiracil plus bevacizumab. To our knowledge, this represents the first report describing use of this combination in the third-line setting for metastatic urachal carcinoma. Overall survival was 27 months. This case is hypothesis-generating for the use of modern CRC-based therapies, including anti-VEGF–containing combinations.

Related

  1. Hypoxia-induced SATB homeobox 2 increases hypoxia-inducible factor-1-dependent tumorigenesis and drives bevacizumab resistance in lung adenocarcinoma.
    Suhong Ruan, Tengteng Wei, Guangda Yuan +5
    Translational oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Diagnostic challenge in distinguishing intestinal endometriosis-associated carcinoma from primary colorectal adenocarcinoma: a case report
    Norie Tojo, Hisashi Kataoka, Yuko Izumi +2
    Journal of Surgical Case ReportsPeer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
  3. Tumor-to-tumor metastasis of colorectal adenocarcinoma within a gonadotroph pituitary adenoma.
    Shingo Murasawa, Fumiya Isozaki, Miku Fukasawa-Maeda +3
    JCEM case reportsPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  4. Clinical and radiographic improvement in suspected pulmonary lymphangitic carcinomatosis-associated hypoxemic respiratory failure following iruplinalkib-based treatment in ALK-positive lung adenocarcinoma after sequential treatment with ensartinib and lorlatinib: a two-patient case report
    Hanbin Lin, Yuxiong Hu, Haoqiang Li +5
    Frontiers in MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  5. CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target
    Wei Yu, Shengyu Wei, Shiqin Wan +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC

Cite

BibTeXRIS
BibTeX
@article{naib2026sequential,
  title = {{Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report}},
  author = {Shahla Abu Naib and Marco Gerlinger},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1933091},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1933091/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report
AU  - Shahla Abu Naib
AU  - Marco Gerlinger
PY  - 2026
DA  - 2026/10/29
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1933091
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1933091/full
AB  - Urachal adenocarcinoma is a rare malignancy without prospective treatment trials. Management of metastatic disease is typically extrapolated from colorectal cancer (CRC) due to histologic and molecular similarities. An 80-year-old woman with metastatic urachal adenocarcinoma received sequential CRC-based therapy including first-line CAPOX plus bevacizumab, second-line FOLFIRI plus bevacizumab, third-line trifluridine/tipiracil plus bevacizumab, in addition to brief administration of regorafenib and fruquintinib in the fourth- and fifth-line setting. Oxaliplatin was discontinued after one cycle due to worsening of vision on a background of pre-existing retinopathy. The longest disease control (time to progression ~11 months) occurred with trifluridine/tipiracil plus bevacizumab. To our knowledge, this represents the first report describing use of this combination in the third-line setting for metastatic urachal carcinoma. Overall survival was 27 months. This case is hypothesis-generating for the use of modern CRC-based therapies, including anti-VEGF–containing combinations.
SN  - 2234-943X
ER  -